Activity of dalbavancin tested against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States

Journal of Clinical Microbiology

Volumn 45, Issue 3, 2007, Pages 998-1004

  Biedenbach, Douglas J ^a   Ross, James E ^a   Fritsche, Thomas R ^a   Sader, Helio S ^a,b   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; DALBAVANACIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; CLINICAL TRIAL; DRUG POTENCY; GEOGRAPHIC DISTRIBUTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OXACILLIN; STAPHYLOCOCCUS; STREPTOCOCCUS; TEICOPLANIN; UNITED STATES; VANCOMYCIN;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 33947246227     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02368-06     Document Type: Article

References (26)

1. Anderegg, T. R., D. J. Biedenbach, and R. N. Jones. 2003. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity. J. Clin. Microbiol. 41:2795-2796.
2. Biedenbach, D. J., J. M. Stephen, and R. N. Jones. 2003. Antimicrobial susceptibility profile among β-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program-North America, 2001. Diagn. Microbiol. Infect. Dis. 46:291-294.
3. Biedenbach, D. J., M. A. Toleman, T. R. Walsh, and R. N. Jones. 2006. Characterization of fluoroquinolone-resistant β-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn. Microbiol. Infect. Dis. 55:119-127.
4. Bowker, K. E., A. R. Noel, and A. P. Macgowan. 2006. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J. Antimicrob Chemother. 58:802-805.
5. Carmeli, Y., C. Rothermel, D. Sheehan, P. Hogan, and M. Mendelson. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. L-1211.
6. CLSI. 2006. Performance standards for antimicrobial disk susceptibility tests, 9th edition. Approved standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Ergin, A., S. Ercis, and G. Hascelik. 2003. In vitro susceptibility, tolerance and MLS resistance phenotypes of group C and group G streptococci isolated in Turkey between 1995 and 2002. Int. J. Antimicrob. Agents 22:160-163.
9. Fritsche, T. R., R. P. Rennie, B. P. Goldstein, and R. N. Jones. 2006. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms. J. Clin. Microbiol. 44:2988-2990.
10. Goldstein, E. J., D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. T. Fernandez. 2006. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother. 50:2875-2879.
11. Hanslik, T., C. Hartig, C. Jurand, L. Armand-Lefevre, V. Jubault, E. Rouveix, O. Dubourg, J. Prinseau, A. Baglin, and M. H. Nicolas-Chanoine. 2003. Clinical significance of tolerant strains of streptococci in adults with infective endocarditis. Clin. Microbiol. Infect. 9:852-857.
12. Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O'Riordan. 2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41:1407-1415.
13. Johnson, D. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2006. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int. J. Antimicrob. Agents 27:557-560.
14. Jones, R. N., J. M. Streit, and T. R. Fritsche. 2004. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int. J. Antimicrob. Agents 23:197-199.
15. Jones, R. N., T. R. Fritsche, H. S. Sader, and B. P. Goldstein. 2005. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. 17:593-600.
16. Jones, R. N., H. S. Sader, T. R. Fritsche, P. A. Hogan, and D. J. Sheehan. 2006. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. 44:2622-2625.
17. Jones, R. N., M. G. Stilwell, H. S. Sader, T. R. Fritsche, and B. P. Goldstein. 2006. Spectrum and potency of dalbavancin tested against 3,322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 54:149-153.
18. Lin, S. W., P. L. Carver, and D. D. DePestel. 2006. Dalbavancin: a new option for the treatment of Gram-positive infections. Ann. Pharmacother. 40:449-460.
19. Lopez, S., C. Hackbarth, G. Romano, J. Trias, D. Jabes, and B. P. Goldstein. 2005. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 55(Suppl. 2):ii21-ii24.
20. Moet, G. J., R. N. Jones, D. J. Biedenbach, M. G. Stilwell, and T. R. Fritsche. 2007. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn. Microbiol. Infect. Dis. 57:7-13
21. Pope, S. D., and A. M. Roecker. 2006. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 26:908-918.
22. Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, and T. Henkel. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37:1298-1303.
23. Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48:137-143.
24. Streit, J. M., H. S. Sader, T. R. Fritsche, and R. N. Jones. 2005. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. 53:307-310.
25. Zaoutis, T., B. Schneider, L. Steele Moore, and J. D. Klein. 1999. Antibiotic susceptibilities of group C and group G streptococci isolated from patients with invasive infections: evidence of vancomycin tolerance among group G serotypes. J. Clin. Microbiol. 37:3380-3383.
26. Zhu, L. X., Z. W. Zhang, C. Wang, H. W. Yang, Q. Zhang, and J. Cheng. 2006. Evaluation of the CLSI cefoxitin 30-μg disk-diffusion method for detecting methicillin resistance in staphylococci. Clin. Microbiol. Infect. 12: 1039-1042.